| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/30/2011 | EP2300055A1 Anticancer combination therapy including triciribine |
| 03/30/2011 | EP2300036A1 Melanocortin receptor-specific peptides for treatment of sexual dysfunction |
| 03/30/2011 | EP2300032A2 Metal abstraction peptide (map) tag and associated methods |
| 03/30/2011 | EP2300031A2 Methods and compositions for oral administration of exenatide |
| 03/30/2011 | EP2300030A2 Rice bran extracts and methods of use thereof |
| 03/30/2011 | EP2300029A2 Rice bran extracts for inflammation and methods of use thereof |
| 03/30/2011 | EP2300028A1 Pharmaceutical composition comprising extracts of huanglian and ku ding cha effective for lowering blood lipid levels |
| 03/30/2011 | EP2300021A2 A conjugate of a polymer, an anti-angiogenesis agent and a targeting moiety, and uses thereof in the treatment of bone related angiogenesis conditions |
| 03/30/2011 | EP2300020A2 Nutritive compositions and methods of using same |
| 03/30/2011 | EP2300019A2 Antisense formulation |
| 03/30/2011 | EP2300018A1 Paeoniflorin preparations and uses thereof for fat reduction |
| 03/30/2011 | EP2300017A2 Mirnas as therapeutic targets in cancer |
| 03/30/2011 | EP2300016A1 6-substituted estradiol derivatives and methods of use |
| 03/30/2011 | EP2300015A1 Use of gabaa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness |
| 03/30/2011 | EP2300014A1 Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis |
| 03/30/2011 | EP2300013A1 Phosphorous derivatives as kinase inhibitors |
| 03/30/2011 | EP2300012A2 Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |
| 03/30/2011 | EP2300011A1 Therapeutic methods and compounds |
| 03/30/2011 | EP2300010A2 Organic compounds |
| 03/30/2011 | EP2300009A1 Oral administration of peripherally-acting opioid antagonists |
| 03/30/2011 | EP2300008A1 Supplementation of propane-1,2,3-triol and water in fasting subjects |
| 03/30/2011 | EP2300007A1 N-piperidinyl acetamide derivatives as calcium channel blockers |
| 03/30/2011 | EP2300006A1 Colon cleansing method and kit |
| 03/30/2011 | EP2300005A1 Small molecule inhibitors of botulinum neurotoxins |
| 03/30/2011 | EP2300004A2 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| 03/30/2011 | EP2300003A2 Methods for treating injury associated with exposure to an alkylating species |
| 03/30/2011 | EP2300002A1 Escalating dosing regimen for effecting weight loss and treating obesity |
| 03/30/2011 | EP2300001A1 Dronedarone for the prevention of permanent atrial fibrillation |
| 03/30/2011 | EP2300000A1 Methods and compositions for reducing inflammation and treating inflammatory disorders |
| 03/30/2011 | EP2299999A1 Stat3 inhibitors |
| 03/30/2011 | EP2299998A1 Medium-chain length fatty acids and glycerides as nephroprotection agents |
| 03/30/2011 | EP2299997A2 Use of nitrated lipids for treatment of side effects of toxic medical therapies |
| 03/30/2011 | EP2299996A1 5-lipoxygenase inhibitors |
| 03/30/2011 | EP2299995A1 Combination of amidine derivates with cyclic depsipeptides |
| 03/30/2011 | EP2299994A1 L-carnitine and alkanoyl l-carnitine phytates and process for preparing the same |
| 03/30/2011 | EP2299993A1 Process for purifying rasagiline base |
| 03/30/2011 | EP2299992A2 Process for preparing and drying solid rasagiline base |
| 03/30/2011 | EP2299991A1 A method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin k |
| 03/30/2011 | EP2299990A1 Novel embedment particles for inhalation |
| 03/30/2011 | EP2299987A1 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
| 03/30/2011 | EP2299984A1 Oral formulations of cytidine analogs and methods of use thereof |
| 03/30/2011 | EP2299981A1 Sublingual compositions comprising (2s) - (4e) -n-methyl-5- (3- (5-isopropoxypyridin) yl) -4-penten-2-amine |
| 03/30/2011 | EP2299978A1 Single dosage pharmaceutical formulation comprising eprosartan mesylate |
| 03/30/2011 | EP2299977A2 Liposomes for drug delivery and methods for preparation thereof |
| 03/30/2011 | EP2299976A2 Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| 03/30/2011 | EP2299974A1 Pharmaceutical compositions containing a fluoroquinolone antibiotic drug |
| 03/30/2011 | EP2299973A1 Pharmaceutical preparation comprising permethylated cyclodextrin |
| 03/30/2011 | EP2299971A1 Solid pharmaceutical formulations comprising bibw 2992 |
| 03/30/2011 | EP2299826A1 Compositions and methods for attenuating the formation of a2e in the retinal pigment epithelium |
| 03/30/2011 | EP2299824A1 Pyrazole derivatives useful as inhibitors of faah |
| 03/30/2011 | EP2299823A1 Pyrimidine non-classical cannabinoid compounds and related methods of use |
| 03/30/2011 | EP2299822A2 Method for treating neurodegenerative dysfunction |
| 03/30/2011 | EP2299820A1 Ophthalmic formulation of rho kinase inhibitor compound |
| 03/30/2011 | EP2299819A1 Pyridine non-classical cannabinoid compounds and related methods of use |
| 03/30/2011 | EP2299818A1 Pyrimidine classical cannabinoid compounds and related methods of use |
| 03/30/2011 | EP2299817A1 Pyridine classical cannabinoid compounds and related methods of use |
| 03/30/2011 | EP2299816A1 Inhibitors of janus kinases |
| 03/30/2011 | EP2299815A1 Method of treating burns using avermectin compound |
| 03/30/2011 | EP2299814A1 Compositions, synthesis, and methods of using piperazine based antipsychotic agents |
| 03/30/2011 | EP2299813A1 Branched 3- and 6-substituted quinolines as cgrp receptor antagonists |
| 03/30/2011 | EP2299810A1 Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent |
| 03/30/2011 | EP2299809A1 Substituted cyclohexylidene-ethylidene-octahydro-indene compounds |
| 03/30/2011 | EP2222376B1 3-(2,2,2-trimethylhydrazinium) propionate salts for treating myocardial infarction |
| 03/30/2011 | EP2217597B1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| 03/30/2011 | EP2178513B1 Tableted compositions containing atazanavir |
| 03/30/2011 | EP2176259B1 Fused imidazoles for cancer treatment |
| 03/30/2011 | EP2150253B1 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas |
| 03/30/2011 | EP2131823B1 Rapid-disintegration monolayer film for the oral administration of active substances |
| 03/30/2011 | EP2125736B1 Substituted acetophenones useful as pde4 inhibitors |
| 03/30/2011 | EP2081934B1 Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound |
| 03/30/2011 | EP2057125B1 Non-nucleoside reverse transcriptase inhibitors |
| 03/30/2011 | EP2054165B1 Method of covering self-assembled metal or inorganic surfaces with gem-bisphosphonic compounds and uses thereof |
| 03/30/2011 | EP2054040B1 Method for making solid dispersions of midostaurin |
| 03/30/2011 | EP2037897B1 An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof |
| 03/30/2011 | EP1951739B1 An improved process for the isolation of arjunic acid from the bark of the tree terminalia arjuna and the use of this compound in the treatment of cancer |
| 03/30/2011 | EP1940835B1 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| 03/30/2011 | EP1937687B1 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE |
| 03/30/2011 | EP1902034B1 Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| 03/30/2011 | EP1898908B1 Novel chemical compounds and the uses thereof as a medicament |
| 03/30/2011 | EP1877403B1 Mono-lysine salts of azole compounds |
| 03/30/2011 | EP1856066B1 Anti-cancer and anti-microbial oxazolidinones and analogues |
| 03/30/2011 | EP1843789B1 Compositions and methods for treating fibrotic disorders |
| 03/30/2011 | EP1838674B1 Heteroaryl sulfonamides and ccr2 |
| 03/30/2011 | EP1838392B1 Selenium-containing medicaments for the prevention or treatment of endothelial vascular diseases |
| 03/30/2011 | EP1833821B1 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 03/30/2011 | EP1829536B1 Ameliorant for renal insufficiency |
| 03/30/2011 | EP1807083B1 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| 03/30/2011 | EP1804919B1 Cgrp receptor antagonists |
| 03/30/2011 | EP1802297B1 Compositions and methods for treatment of disease caused by yersinia spp infection |
| 03/30/2011 | EP1775289B1 Novel imidazolidine derivatives |
| 03/30/2011 | EP1622579B1 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
| 03/30/2011 | EP1601643B1 Arylcycloalkyl derivatives with branched side chains as ppar receptor modulators, method for their production and their use as medicaments |
| 03/30/2011 | EP1558586B1 Inhibitors of akt activity |
| 03/30/2011 | EP1507515B1 Free-flowing, powdery composition containing alpha-liponic acid (-derivatives) |
| 03/30/2011 | EP1506172B1 Hepatitis c virus inhibitors |
| 03/30/2011 | EP1503773B1 Hepatoprotective activity of 2 -p-hydroxybenzoylmussaenosidic acid |
| 03/30/2011 | EP1458888B1 Methods of treating psychosis and schizophrenia based on polymorphisms in the cntf gene |
| 03/30/2011 | EP1441719B1 N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors |
| 03/30/2011 | EP1392381B1 An aerosol forming device for use in inhalation therapy |
| 03/30/2011 | EP1355658B1 Anti HER3 antibody for diagnosis, prevention and treatment of hyperproliferative diseases |